There Might be a Risk of Anaphylaxis Due to Omalizumab (Anti-IgE) Therapy
作者： AD Yalcin , K Suer , AN Yalcin , None
关键词:
摘要: Omalizumab, a humanized mAb that binds to the CH3 domain, near binding site for high-affinity type-I IgE Fc receptors of human IgE, can neutralize free and inhibit allergic pathway without sensitizing mast cell basophils. The clinical experience during patient follow-up an omalizumab treated severe persistent asthma with complicated viral infection is introduced. A female (aged 58) asthma, on therapy had laryngeal oedema common cold bacterial sinusitis after injection. Systemic steroids, ketotifen fumarate, antibiotic antihistamines (desloratadine) were given. We did not stop therapy. To our knowledge, this first time association between use has been documented. In fact we do know exact mechanism behind relationship. conclusion suggest Omalizumab five days infections such as sinus infections.
symbiosisonlinepublishing.com参考文章(22)
Rebecca Normansell, Samantha Walker, Stephen J Milan, E. Haydn Walters, Parameswaran Nair, Omalizumab for asthma in adults and children. Cochrane Database of Systematic Reviews. pp. 1- 159 ,(2014) , 10.1002/14651858.CD003559.PUB4
Lusmaia D.C. Costa, Paulo Sucasas Costa, Paulo A.M. Camargos, Exacerbation of asthma and airway infection: is the virus the villain? Jornal De Pediatria. ,vol. 90, pp. 542- 555 ,(2014) , 10.1016/J.JPED.2014.07.001
Koichi Asai, Jiro Kitaura, Yuko Kawakami, Noboru Yamagata, Mindy Tsai, David P Carbone, Fu-Tong Liu, Stephen J Galli, Toshiaki Kawakami, Regulation of mast cell survival by IgE. Immunity. ,vol. 14, pp. 791- 800 ,(2001) , 10.1016/S1074-7613(01)00157-1
Janet Kalesnikoff, Michael Huber, Vivian Lam, Jacqueline E Damen, Juan Zhang, Reuben P Siraganian, Gerald Krystal, Monomeric IgE stimulates signaling pathways in mast cells that lead to cytokine production and cell survival. Immunity. ,vol. 14, pp. 801- 811 ,(2001) , 10.1016/S1074-7613(01)00159-5
Janine Beale, Annabelle Jayaraman, David J Jackson, Jonathan DR Macintyre, Michael R Edwards, Ross P Walton, Jie Zhu, Yee Man Ching, Betty Shamji, Matt Edwards, John Westwick, David J Cousins, You Yi Hwang, Andrew McKenzie, Sebastian L Johnston, Nathan W Bartlett, None, Rhinovirus-induced IL-25 in asthma exacerbation drives type 2 immunity and allergic pulmonary inflammation Science Translational Medicine. ,vol. 6, ,(2014) , 10.1126/SCITRANSLMED.3009124
M. Humbert, R. Beasley, J. Ayres, R. Slavin, J. Hébert, J. Bousquet, K.-M. Beeh, S. Ramos, G. W. Canonica, S. Hedgecock, H. Fox, M. Blogg, K. Surrey, Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE Allergy. ,vol. 60, pp. 309- 316 ,(2005) , 10.1111/J.1398-9995.2004.00772.X
Mathieu Molimard, Frédéric de Blay, Alain Didier, Vincent Le Gros, Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France. Respiratory Medicine. ,vol. 102, pp. 71- 76 ,(2008) , 10.1016/J.RMED.2007.08.006
Eleni G. Tzortzaki, Andreas Georgiou, Dimitrios Kampas, Marinos Lemessios, Miltiadis Markatos, Tonia Adamidi, Katerina Samara, Georgia Skoula, Aggeliki Damianaki, Sophia Schiza, Nikos Tzanakis, Nikolaos M. Siafakas, Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean "real-life" experience. Pulmonary Pharmacology & Therapeutics. ,vol. 25, pp. 77- 82 ,(2012) , 10.1016/J.PUPT.2011.11.004
María Del Carmen Vennera, Luis Perez de Llano, Santiago Bardagí, Pilar Ausin, Carles Sanjuas, Héctor González, José A Gullón, Eva Martínez-Moragón, José A Carretero, Elisabet Vera, Juan F Medina, Francisco J Alvarez, Luis M Entrenas, Alicia Padilla, Rosa Irigaray, César Picado, Spanish Registry, None, Omalizumab Therapy in Severe Asthma: Experience from the Spanish Registry—Some New Approaches Journal of Asthma. ,vol. 49, pp. 416- 422 ,(2012) , 10.3109/02770903.2012.668255
S. Korn, A. Thielen, S. Seyfried, C. Taube, O. Kornmann, R. Buhl, Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany. Respiratory Medicine. ,vol. 103, pp. 1725- 1731 ,(2009) , 10.1016/J.RMED.2009.05.002